GlassScriptPhysician profile
Nancy J Andrews
NPI 1427077916
$20,350.41
in general payments reported to CMS, 2019-2025
60 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,010 · 2020: $2,536 · 2021: $3,431 · 2022: $3,536 · 2023: $2,802 · 2024: $2,242 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,494 · Honoraria: $300 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,493.71 |
| Honoraria | $300.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,435.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,392.42 | 2019-2025 | Evenity, Repatha, Tepezza |
| Lilly USA, LLC | $1,341.59 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,313.05 | 2019-2025 | |
| Medtronic, INC. | $1,229.24 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Abbvie INC. | $1,038.30 | 2019-2025 | Synthroid |
| Astrazeneca Pharmaceuticals LP | $911.34 | 2019-2024 | Farxiga |
| Mannkind Corporation | $838.01 | 2019-2025 | Afrezza |
| Dexcom, INC. | $760.24 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.34 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amneal Pharmaceuticals LLC | $679.14 | 2019-2025 | Unithroid |
| Abbott Laboratories | $623.78 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $566.52 | 2019-2023 | |
| Medtronic Minimed, INC. | $474.50 | 2019-2020 | |
| Insulet Corporation | $455.13 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.